country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-121889

Copy Link Print Information

FQ

FQ is a tyrosinase inhibitor that effectively inhibits the diphenolase activity of mushroom tyrosinase (IC₅₀=120 μM). FQ can be used in the study of pigmentation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 190838-76-7
Formel: C₁₄H₉FN₂O
Molecular Weight:240.23

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (267 KB)

FQ Chemical Structure

CAS. Nr.: 190838-76-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- Clinical Trial
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

FQ is a tyrosinase inhibitor that effectively inhibits the diphenolase activity of mushroom tyrosinase (IC₅₀=120 μM). FQ can be used in the study of pigmentation^[1].

IC₅₀ & Target

IC50：120 μM (Tyrosinase Diphenolase) ^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	ED₅₀	>20 μg/mL Compound: 10	In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation	[PMID: 11354375]
A549	ED₅₀	7.5 μg/mL Compound: 10	In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation	[PMID: 11354375]
COLO 205	IC₅₀	10 μM Compound: 9b	Antiproliferative activity against human COLO205 cells by MTT assay Antiproliferative activity against human COLO205 cells by MTT assay	[PMID: 22749421]
H9	EC₅₀	9.18 μM Compound: 10	Concentration required to inhibit viral replication in acutely infected H9 lymphocytes when tested for anti-HIV activity Concentration required to inhibit viral replication in acutely infected H9 lymphocytes when tested for anti-HIV activity	[PMID: 11354375]
H9	IC₅₀	38.8 μM Compound: 10	Concentration required to inhibit uninfected H9 cell growth when tested for anti-HIV activity Concentration required to inhibit uninfected H9 cell growth when tested for anti-HIV activity	[PMID: 11354375]
K562	IC₅₀	17 μM Compound: 9b	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 22749421]
KB	ED₅₀	>20 μg/mL Compound: 10	In vitro effective concentration required to reduce the number of Human epidermoid carcinoma cells (KB) of nasopharynx after 3-day incubation In vitro effective concentration required to reduce the number of Human epidermoid carcinoma cells (KB) of nasopharynx after 3-day incubation	[PMID: 11354375]
KB	ED₅₀	6.5 μg/mL Compound: 10	In vitro effective concentration required to reduce the number of P-glycoprotein-expressing human epidermoid carcinoma cells (KB-VIN) of nasopharynx after 3-day incubation In vitro effective concentration required to reduce the number of P-glycoprotein-expressing human epidermoid carcinoma cells (KB-VIN) of nasopharynx after 3-day incubation	[PMID: 11354375]
MCF7	ED₅₀	>20 μg/mL Compound: 10	In vitro effective concentration required to reduce the number of human breast cancer (MCF-7) after 3-day incubation In vitro effective concentration required to reduce the number of human breast cancer (MCF-7) after 3-day incubation	[PMID: 11354375]
MDA-MB-231	IC₅₀	20 μM Compound: 9b	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 22749421]
Sf21	IC₅₀	1102 nM Compound: 13f	Inhibition of N-terminal GST-tagged human TNKS-2 (849 to 1166 residues) expressed in in insect sf21 cells preincubated for 2 hrs followed by substrate addition measured after 30 mins Inhibition of N-terminal GST-tagged human TNKS-2 (849 to 1166 residues) expressed in in insect sf21 cells preincubated for 2 hrs followed by substrate addition measured after 30 mins	[PMID: 27163581]
SK-MEL-2	ED₅₀	>20 μg/mL Compound: 10	In vitro effective concentration required to reduce the number of human melanoma cancer (SKMEL-2) after 3-day incubation In vitro effective concentration required to reduce the number of human melanoma cancer (SKMEL-2) after 3-day incubation	[PMID: 11354375]

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 190838-76-7
Molecular Weight 240.23
Formel C₁₄H₉FN₂O
SMILES

O=C1N=C(NC2=C1C=CC=C2)C3=CC=C(C=C3)F
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (267 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wang R, et al. 2-(4-Fluorophenyl)-quinazolin-4(3H)-one as a novel tyrosinase inhibitor: Synthesis, inhibitory activity, and mechanism. Bioorg Med Chem. 2016 Oct 1;24(19):4620-4625. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen